Risk Stratification Among Individuals Who Have Many Moles on Their Skin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

73 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-03-09

Study Completion Date

2025-11-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators are doing this study to improve our ability to identify which people with many moles on their skin are most likely to develop skin melanoma. The investigators hope to identify features of moles that are associated with melanoma risk. The investigators hope to use this information to customize and tailor melanoma screening to the individual patient based on a better estimate of their individual risk.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MoleGazer Development Feasibility Study

NCT05015816

Melanoma (Skin) Moles Multiple Benign

ACTIVE_NOT_RECRUITING NA

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

NCT00040352

Melanoma Dysplastic Nevus Syndrome

RECRUITING

Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma

NCT03725449

Dysplastic Nevus Health Status Unknown Melanoma +1 more

COMPLETED NA

Melanoma Risk Assessment & Tailored Intervention

NCT01356771

Melanoma Skin Cancer

COMPLETED NA

Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma

NCT03028948

Stage 0 Skin Melanoma Stage I Skin Melanoma Stage IA Skin Melanoma +9 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

High-Risk Nevus Phenotype

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

History of Melanoma (cases)

Participants at high-risk for melanoma (that is, those having many nevi and morphologically atypical nevi) who either have a history of invasive melanoma (cases) or do not have a history of melanoma (controls) and will perform comprehensive total body imaging of their moles in order to identify phenotypic markers of melanoma risk that aid in melanoma risk stratification. In addition, we will investigate histopathologic and molecular features of moles that are associated with melanoma risk and with melanoma subtypes. The evaluations needed for this study protocol will be primarily performed during routine clinical care.

survey

Intervention Type BEHAVIORAL

Research assessments as part of this protocol will be scheduled during routine clinic visits

Saliva samples

Intervention Type OTHER

Germline DNA analysis

No Melanoma History (controls)

Participants at high-risk for melanoma (that is, those having many nevi and morphologically atypical nevi) who either have a history of invasive melanoma (cases) or do not have a history of melanoma (controls) and will perform comprehensive total body imaging of their moles in order to identify phenotypic markers of melanoma risk that aid in melanoma risk stratification. In addition, we will investigate histopathologic and molecular features of moles that are associated with melanoma risk and with melanoma subtypes. The evaluations needed for this study protocol will be primarily performed during routine clinical care.

survey

Intervention Type BEHAVIORAL

Research assessments as part of this protocol will be scheduled during routine clinic visits

Saliva samples

Intervention Type OTHER

Germline DNA analysis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

survey

Research assessments as part of this protocol will be scheduled during routine clinic visits

Intervention Type BEHAVIORAL

Saliva samples

Germline DNA analysis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients ≥ 18 years of age
* High-risk nevus phenotype (≥ 50 nevi (≥ 2mm in size) and ≥ 1 atypical nevus)
* First presented to MSKCC for cutaneous melanoma-related care on or after April 2016
* Cases: diagnoses of unequivocal invasive cutaneous melanomas (AJCC Stages I-IV) confirmed by MSKCC pathology on or after April 2016
* Cases: completion of surgical treatment of primary melanoma
* Ability to sign or verbally consent to the informed consent

Exclusion Criteria

* Controls: Histopathologically borderline melanocytic tumors for which melanoma could not be excluded or that were treated as possible melanomas.
* Known germline high-penetrance melanoma predisposition mutation (that is, CDKN2A, CDK4, and BAP1)
* Cases: history of invasive cutaneous melanoma (AJCC Stages I-IV) not confirmed by MSKCC pathology
* History of acrolentiginous type of cutaneous melanoma or history of mucosal melanoma
* Cases and controls: prior administration of systemic medications known to modify nevus phenotype, including but not limited to: MEK inhibitors (trametinib, cobimetinib, etc.), BRAF inhibitors (vemurafenib, dabrafenib, etc.), and immunotherapy (pembrolizumab, nivolumab, atezolizumab, ipilimumab, etc.). Controls: history of Stage 0-IV melanoma confirmed by MSKCC pathology
* History of limb amputation or other condition (e.g., tattoos, burns) per investigator discretion that would modify nevus phenotype
* Physical inability to undergo total body photography or reflectance confocal microscopy imaging (that is, remain relatively still for durations of 3-5 minutes)
* Known hypersensitivity to adhesive rings used for reflectance confocal microscopy
* Inability to give informed consent
* Have skin afflicted with anther skin condition (for example, psoriasis) that would affect ability to characterize nevus phenotype (per investigator discretion)
* Familial cutaneous melanoma history (families with at least one invasive melanoma and two or more other diagnoses of invasive melanoma or pancreatic cancer among first- or second-degree relatives on the same side of the family). We will confirm melanoma family history via medical record documentation, whenever possible, as recommended by previous studies that disproved about half of the reported family histories of melanoma among first-degree relatives in case-control studies.
* Age 70 or above

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No